JH
Therapeutic Areas
Syros Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tamibarotene (SY-1425) | RARA-positive Higher-Risk MDS | Phase 3 |
| SY-2101 | Acute Promyelocytic Leukemia (APL) | Phase 3 |
| SY-5609 | Solid Tumors | Phase 1/2 |
| SY-5007 | RET-altered Solid Tumors | Preclinical |
Leadership Team at Syros Pharmaceuticals
CC
Conley Chee
Chief Executive Officer
DA
David A. Roth
Chief Medical Officer
ER
Eric R. Olson
Chief Scientific Officer, Co-founder
MK
Marcin Kortylewski
Board Member
KA
Keith A. Katkin
Board Member
NS
Nancy Simonian
Former Chief Executive Officer